Island Pharmaceuticals Limited (ILA.AX)

0.0560 0.0000 (0.00%) As of 10:50AM AEST. Market open.

Island Pharmaceuticals Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 7036 7675
https://www.islandpharmaceuticals.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Paul Donald Richard MacLeman BVSc, D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr	Executive Chairman	164.92k	N/A	1966
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D.	MD, CEO, President & Executive Director	306.7k	N/A	N/A
Mr. Cameron Jones C.A.	Joint Company Secretary	N/A	N/A	N/A
Stephanie Vipond	Joint Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.

Corporate governance

Island Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.